Furthermore, our study revealed that ESRRG promotes the progression of gallbladder cancer via inhibiting tumor immune microenvironment and, notably, for the first time, demonstrated a positive correlation between ESRRG expression and PD-L1 expression in gallbladder cancer. Here, CD274 is linked to gallbladder cancer.